22UK image
Deposition Date 2026-01-23
Release Date 2026-10-21
Last Version Date 2026-10-21
Entry Detail
PDB ID:
22UK
Keywords:
Title:
Crystal structure of human cGAS in complex with NF023
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
2.55 Å
R-Value Free:
0.28
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Cyclic GMP-AMP synthase
Gene (Uniprot):CGAS
Chain IDs:A, B
Chain Length:371
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Suramin and its analogues are multi-functional inhibitors of cGAS.
J.Mol.Biol. ? 170044 170044 (2026)
PMID: 42810574 DOI: 10.1016/j.jmb.2026.170044

Abstact

Upon sensing double-stranded DNA, cyclic GMP-AMP synthase (cGAS) catalyzes ATP and GTP to synthesize the cyclic dinucleotide 2',3'-cGAMP, which subsequently activates stimulator of interferon genes (STING)-mediated immune responses. Modulation of cGAS catalytic activity is crucial for treating diseases associated with the cGAS-STING pathway. Here, we found that suramin and its analogues, such as NF023, can inhibit 2',3'-cGAMP synthesis by competitively binding to cGAS. Structural analysis of the cGAS-NF023 complex reveals that NF023 binds to the active-site cleft and DNA-binding sites of cGAS, which prevents substrate access to the active site, stabilizes the activation loop in an inactive conformation and blocks cGAS-DNA binding. In addition, both suramin and NF023 disrupt cGAS-DNA phase separation, thereby potentially impairing cytosolic DNA sensing and downstream signal transduction. These findings unveil the unique mechanisms underlying cGAS inhibition by suramin and its analogues and provide the structural basis for developing cGAS inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback